Keywords
Last Name
Institution

BANU K ARUN

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94. PMID: 29059683.
      View in: PubMed
    2. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila). 2017 Nov; 10(11):641-650. PMID: 28877935.
      View in: PubMed
    3. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691. PMID: 28346442.
      View in: PubMed
    4. Ratcliff CG, Milbury K, Chandwani KD, Chaoul A, Perkins G, Nagarathna R, Haddad R, Nagendra HR, Raghuram NV, Spelman A, Arun B, Wei Q, Cohen L. Examining Mediators and Moderators of Yoga for Women With Breast Cancer Undergoing Radiotherapy. Integr Cancer Ther. 2016 Sep; 15(3):250-62. PMID: 26867802; PMCID: PMC4972683 [Available on 09/01/16].
    5. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73. PMID: 26706041.
      View in: PubMed
    6. Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, Richards-Kortum R, Jia W, Seewaldt VL, Yu D. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Res. 2015 Nov 15; 75(22):4863-75. PMID: 26383165.
      View in: PubMed
    7. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM, Syngal S, Wollins DS, Lindor NM. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015 Nov 1; 33(31):3660-7. PMID: 26324357.
      View in: PubMed
    8. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer. Biomark Cancer. 2015; 7:39-49. PMID: 26327783.
      View in: PubMed
    9. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 1; 121(19):3422-7. PMID: 26280679.
      View in: PubMed
    10. Woodson AH, Profato JL, Rizvi SH, Elsayegh N, Rieber AG, Arun BK. Service Delivery Model and Experiences in a Cancer Genetics Clinic for an Underserved Population. J Health Care Poor Underserved. 2015 Aug; 26(3):784-91. PMID: 26320913.
      View in: PubMed
    11. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):417. PMID: 26092296.
      View in: PubMed
    12. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):880-915. PMID: 26150582.
      View in: PubMed
    13. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015 Jul; 152(2):407-16. PMID: 26017070.
      View in: PubMed
    14. Litton JK, Lee JH, Arun BK. Reply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer. 2015 Sep 1; 121(17):3047. PMID: 26018033.
      View in: PubMed
    15. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer. 2015; 6(7):610-5. PMID: 26078790.
      View in: PubMed
    16. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol. 2015 Jul; 47(1):262-8. PMID: 25975349.
      View in: PubMed
    17. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobágyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7. PMID: 25948675.
      View in: PubMed
    18. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015; 17:61. PMID: 25925750.
      View in: PubMed
    19. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 7; 313(13):1347-61. PMID: 25849179.
      View in: PubMed
    20. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 2015; 10(4):e0120020. PMID: 25830658.
      View in: PubMed
    21. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015 May-Jun; 21(3):260-7. PMID: 25789811.
      View in: PubMed
    22. Profato JL, Arun BK. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):1-5. PMID: 25502427.
      View in: PubMed
    23. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014; 16(6):3416. PMID: 25919761; PMCID: PMC4406179.
    24. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol. 2015 Jan; 111(1):66-80. PMID: 25381882.
      View in: PubMed
    25. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gómez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jønson L, Osorio A, Martínez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):308-16. PMID: 25336561; PMCID: PMC4294951.
    26. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast. 2014 Dec; 23(6):770-4. PMID: 25231195.
      View in: PubMed
    27. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75. PMID: 25224030; PMCID: PMC4293332.
    28. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobágyi GN, Arun B, Peterson SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist. 2014 Aug; 19(8):797-804. PMID: 24951607; PMCID: PMC4122483.
    29. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer. 2014 Jun; 13(2):291-9. PMID: 24072553; PMCID: PMC4159051.
    30. Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72. PMID: 24796968.
      View in: PubMed
    31. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology. 2014 Nov; 23(11):1220-8. PMID: 24706506.
      View in: PubMed
    32. Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 Apr; 10(4):e1004256. PMID: 24698998; PMCID: PMC3974638.
    33. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer. 2014; 5(5):351-9. PMID: 24723978.
      View in: PubMed
    34. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet. 2015 Jun; 28(3):272-82. PMID: 24646362; PMCID: PMC4205214.
    35. Chandwani KD, Perkins G, Nagendra HR, Raghuram NV, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Haddad R, Morris GS, Scheetz J, Chaoul A, Cohen L. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol. 2014 Apr 1; 32(10):1058-65. PMID: 24590636.
      View in: PubMed
    36. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64. PMID: 24522996.
      View in: PubMed
    37. Biswas S, Arun B, Parmigiani G. Reclassification of predictions for uncovering subgroup specific improvement. Stat Med. 2014 May 20; 33(11):1914-27. PMID: 24353130; PMCID: PMC4008681.
    38. Arun B, Manohari M, Mathiyarasu R, Rajagopal V, Jose MT. Prediction of background in low-energy spectrum of Phoswich detector. Radiat Prot Dosimetry. 2014 Dec; 162(3):260-7. PMID: 24300341.
      View in: PubMed
    39. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z. Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ? 55 years. Mol Carcinog. 2015 Apr; 54(4):281-90. PMID: 24166930.
      View in: PubMed
    40. Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer. 2013; 4(5):433-46. PMID: 23833688; PMCID: PMC3701813.
    41. Bayraktar S, Avery T, Altundag K, Broglio K, Arun BK. Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients. Breast J. 2013 Jul-Aug; 19(4):431-4. PMID: 23701522.
      View in: PubMed
    42. Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2013 Jun; 139(2):571-9. PMID: 23690142; PMCID: PMC3699331.
    43. Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B, Palmer JL, Taylor J, Cohen L. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013 Oct; 22(10):2354-63. PMID: 23657969.
      View in: PubMed
    44. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500. PMID: 23635555; PMCID: PMC3662839.
    45. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013 Apr; 45(4):371-84, 384e1-2. PMID: 23535731; PMCID: PMC3670748.
    46. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212. PMID: 23544013; PMCID: PMC3609646.
    47. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis. 2013 Jun; 30(5):631-42. PMID: 23370825; PMCID: PMC3857726.
    48. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7. PMID: 23337751; PMCID: PMC3568679.
    49. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91. PMID: 23231005; PMCID: PMC4437798.
    50. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013 Apr; 20(4):1267-74. PMID: 23224828.
      View in: PubMed
    51. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      View in: PubMed
    52. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54. PMID: 22827973; PMCID: PMC3816771.
    53. Arun B, Gopinath B, Sharma S. Plant growth promoting potential of bacteria isolated on N free media from rhizosphere of Cassia occidentalis. World J Microbiol Biotechnol. 2012 Sep; 28(9):2849-57. PMID: 22806725.
      View in: PubMed
    54. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84. PMID: 22622473; PMCID: PMC3854959.
    55. de la Cruz J, Andre F, Harrell RK, Bassett RL, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012 Nov; 43(11):1932-9. PMID: 22591913.
      View in: PubMed
    56. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol. 2012 May; 4(3):107-12. PMID: 22590484.
      View in: PubMed
    57. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J. 2012 May-Jun; 18(3):261-6. PMID: 22583196.
      View in: PubMed
    58. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41. PMID: 22392043; PMCID: PMC3855009.
    59. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012 May; 133(1):347-55. PMID: 22270937.
      View in: PubMed
    60. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother. 2012 Feb; 13(3):325-31. PMID: 22242911.
      View in: PubMed
    61. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun BK, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat. 2012 Apr; 132(3):1147-55. PMID: 22218884; PMCID: PMC3523666.
    62. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer. 2011 Dec; 10(4):673-9. PMID: 21681553.
      View in: PubMed
    63. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82. PMID: 22102688.
      View in: PubMed
    64. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783.
      View in: PubMed
    65. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5. PMID: 21913181; PMCID: PMC4369377.
    66. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 1; 29(28):3739-46. PMID: 21900106; PMCID: PMC4874218.
    67. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22. PMID: 22009639; PMCID: PMC4407692.
    68. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53. PMID: 21830012; PMCID: PMC4334122.
    69. Euhus D, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt K, Xia W, O'Shaughnessy J, Grant M, Arun B, Dooley W, Miller A, Flockhart D, Lewis C. Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction. Cancer Prev Res (Phila). 2011 Nov; 4(11):1852-62. PMID: 21778330; PMCID: PMC3208724.
    70. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13. PMID: 21761402; PMCID: PMC3527897.
    71. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503. PMID: 21441069.
      View in: PubMed
    72. Arun B, Pearson J, Chalmers R. Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Clin Exp Dermatol. 2011 Jul; 36(5):509-11. PMID: 21507038.
      View in: PubMed
    73. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8. PMID: 21476105.
      View in: PubMed
    74. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 1; 117(17):3900-7. PMID: 21365619.
      View in: PubMed
    75. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J. 2011 Mar-Apr; 17(2):210-2. PMID: 21294809.
      View in: PubMed
    76. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 1; 17(5):1082-9. PMID: 21233401.
      View in: PubMed
    77. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67. PMID: 21656744.
      View in: PubMed
    78. Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, Le-Petross C, Dogan B, McKenna BJ, Markman M, Babiera G. External qigong therapy for women with breast cancer prior to surgery. Integr Cancer Ther. 2010 Dec; 9(4):348-53. PMID: 21106615.
      View in: PubMed
    79. Arun B, Harries M, Jamieson L, Fitzgerald DA. Multiple nodules on the arms and legs. Clin Exp Dermatol. 2010 Dec; 35(8):931-2. PMID: 21054487.
      View in: PubMed
    80. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹° p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther. 2010 Nov; 9(11):3090-9. PMID: 21045138.
      View in: PubMed
    81. Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw. 2010 Oct; 8(10):1148-55. PMID: 20971839.
      View in: PubMed
    82. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010 Oct; 8(10):1112-46. PMID: 20971838.
      View in: PubMed
    83. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer. 2010 Sep; 9(3):479-87. PMID: 20431955.
      View in: PubMed
    84. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4214-20. PMID: 20733129.
      View in: PubMed
    85. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010 Sep 1; 28(25):3917-21. PMID: 20679610.
      View in: PubMed
    86. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: large and small trials. Semin Oncol. 2010 Aug; 37(4):367-83. PMID: 20816507.
      View in: PubMed
    87. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34. PMID: 20647335; PMCID: PMC4340054.
    88. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):235-44. PMID: 20609467.
      View in: PubMed
    89. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010 Jun; 28(5):554-9. PMID: 20210524.
      View in: PubMed
    90. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7. PMID: 20423989.
      View in: PubMed
    91. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51. PMID: 20309627; PMCID: PMC2925060.
    92. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol. 2010 Mar; 6(3):355-65. PMID: 20222793.
      View in: PubMed
    93. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb; 120(1):111-8. PMID: 20054647.
      View in: PubMed
    94. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR, Wei Q, Cohen L. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol. 2010; 8(2):43-55. PMID: 20388445.
      View in: PubMed
    95. Dorairajan N, Andappan A, Arun B, Siddharth D, Meena M. Day care surgery in a metropolitan government hospital setting--Indian scenario. Int Surg. 2010 Jan-Mar; 95(1):21-6. PMID: 20480836.
      View in: PubMed
    96. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun BK, Wang LE. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 2010 Jul; 122(1):243-9. PMID: 20033770; PMCID: PMC2883663.
    97. Arun B, Colloby P, Loffeld A. A papule with bluish ring on the chest. Clin Exp Dermatol. 2009 Oct; 34(7):845-6. PMID: 19747344.
      View in: PubMed
    98. Arun B, Jamieson L, Mendonca C. An unusual presentation of lichen sclerosus et atrophicus in a tattoo. Clin Exp Dermatol. 2010 Jun; 35(4):441. PMID: 19758382.
      View in: PubMed
    99. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O, Arun B, Lu K, Bovin N. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol. 2009 Sep; 46(15):3037-49. PMID: 19608278.
      View in: PubMed
    100. Arun B, Coupland S, Parslew R. Cysts and erythematous plaques on the face and scalp. Clin Exp Dermatol. 2009 Jun; 34(4):547-8. PMID: 19522988.
      View in: PubMed
    101. Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 1; 27(19):3235-58. PMID: 19470930; PMCID: PMC2716943.
    102. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604. PMID: 19280625.
      View in: PubMed
    103. Arun B, Loffeld A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin Exp Dermatol. 2009 Dec; 34(8):920-1. PMID: 19323659.
      View in: PubMed
    104. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1139-48. PMID: 19294387.
      View in: PubMed
    105. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 1; 115(5):962-71. PMID: 19172584.
      View in: PubMed
    106. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14. PMID: 19241157.
      View in: PubMed
    107. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30. PMID: 19127556.
      View in: PubMed
    108. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7. PMID: 19174581; PMCID: PMC4520422.
    109. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J. 2009 Jan-Feb; 15(1):4-16. PMID: 19141130; PMCID: PMC3756316.
    110. Arun B, Jacob J, Byrne JP. An uncommon burn. Br J Dermatol. 2009 Jan; 160(1):197. PMID: 19143042.
      View in: PubMed
    111. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun BK, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88. PMID: 19064970.
      View in: PubMed
    112. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008 Dec; 16(6):530-4. PMID: 18776816.
      View in: PubMed
    113. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008 Nov 15; 113(10):2627-37. PMID: 18853415.
      View in: PubMed
    114. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008 Sep 10; 26(26):4282-8. PMID: 18779615.
      View in: PubMed
    115. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83. PMID: 18695137.
      View in: PubMed
    116. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8. PMID: 18581139.
      View in: PubMed
    117. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer. 2008 Jul 8; 99(1):68-71. PMID: 18560403; PMCID: PMC2453019.
    118. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol. 2008 Oct; 19(10):1713-9. PMID: 18515258; PMCID: PMC2735063.
    119. Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008; 8:101. PMID: 18410690; PMCID: PMC2362122.
    120. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79. PMID: 18424910.
      View in: PubMed
    121. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 1; 112(7):1455-61. PMID: 18300256.
      View in: PubMed
    122. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008 May-Jun; 14(3):261-7. PMID: 18373644.
      View in: PubMed
    123. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008 Jan-Feb; 14(1):62-8. PMID: 18303485.
      View in: PubMed
    124. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008 Oct; 111(3):405-10. PMID: 18026834.
      View in: PubMed
    125. Johnson CM, Ensor J, Broglio K, Smolenski D, Ravdin P, Amos C, Meric-Bernstam F, Brewster A, Bevers T, Arun B, Berry D. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007; 995. PMID: 18694095.
      View in: PubMed
    126. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol. 2007 Oct 10; 25(29):4635-41. PMID: 17925560.
      View in: PubMed
    127. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer. 2007 Oct 1; 110(7):1445-50. PMID: 17676585.
      View in: PubMed
    128. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH. Breast cancer risk reduction. J Natl Compr Canc Netw. 2007 Sep; 5(8):676-701. PMID: 17927926.
      View in: PubMed
    129. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi GN, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 Aug 15; 13(16):4943-8. PMID: 17699874.
      View in: PubMed
    130. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15; 107(12):2745-51. PMID: 17109443.
      View in: PubMed
    131. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 1; 107(7):1440-7. PMID: 16955504.
      View in: PubMed
    132. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006 Sep 15; 107(6):1348-54. PMID: 16909414.
      View in: PubMed
    133. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Sep 1; 107(5):935-44. PMID: 16874816.
      View in: PubMed
    134. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep; 108(3 Pt 1):515-20. PMID: 16946209.
      View in: PubMed
    135. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun BK, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4274-82. PMID: 16857802.
      View in: PubMed
    136. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    137. Sneige N, Liu B, Yin G, Gong Y, Arun BK. Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol. 2006 May; 19(5):622-9. PMID: 16528376.
      View in: PubMed
    138. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006 Jan 20; 24(3):354-60. PMID: 16421416.
      View in: PubMed
    139. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 1; 106(1):42-50. PMID: 16333852.
      View in: PubMed
    140. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer. 2005 Dec; 12(4):1059-69. PMID: 16322343.
      View in: PubMed
    141. Mangala LS, Arun B, Sahin AA, Mehta K. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer. 2005; 4:33. PMID: 16153302; PMCID: PMC1224867.
    142. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5686-93. PMID: 16115904.
      View in: PubMed
    143. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005 Aug 1; 11(15):5401-9. PMID: 16061854.
      View in: PubMed
    144. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1681-5. PMID: 16030101.
      View in: PubMed
    145. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer. 2005 Jun 15; 103(12):2466-72. PMID: 15852360.
      View in: PubMed
    146. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 7; 102(23):8315-20. PMID: 15914550.
      View in: PubMed
    147. Altundag K, Esteva FJ, Arun B. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anticancer Agents. 2005 Mar; 5(2):99-106. PMID: 15777217.
      View in: PubMed
    148. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1; 23(16):3676-85. PMID: 15738535.
      View in: PubMed
    149. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol. 2005; 26(3):271-4. PMID: 15991524.
      View in: PubMed
    150. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat. 2005 Jan; 89(2):149-57. PMID: 15692757.
      View in: PubMed
    151. Subramanyam SG, Lawrence P, Arun BK. A rare complication of pseudocyst. Trop Doct. 2005 Jan; 35(1):42-3. PMID: 15712548.
      View in: PubMed
    152. Ghei M, Arun B, Maraj BH, Miller RA, Nathan S. Case report: angioleiomyoma of the spermatic cord: a rare scrotal mass. Int Urol Nephrol. 2005; 37(4):731-2. PMID: 16362589.
      View in: PubMed
    153. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 1; 101(9):1977-86. PMID: 15389473.
      View in: PubMed
    154. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004 Jun 15; 22(12):2284-93. PMID: 15136595.
      View in: PubMed
    155. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004 Apr; 31(2 Suppl 7):22-9. PMID: 15179621.
      View in: PubMed
    156. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004 Feb 7; 25(3):94-102. PMID: 14698135.
      View in: PubMed
    157. Altundag K, Altundag O, Gunduz M, Arun B. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen. Med Hypotheses. 2004; 63(5):823-6. PMID: 15488654.
      View in: PubMed
    158. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist. 2004; 9(6):599-605. PMID: 15561804.
      View in: PubMed
    159. Ozguroglu M, Avci B, Turna H, Esen G, Arun B, Celik V, Serdengeçti S. Should mammographic screening be done in primary ovarian cancer?: A case control study in Turkish women. Med Oncol. 2004; 21(2):139-43. PMID: 15299186.
      View in: PubMed
    160. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer. 2003 Dec 15; 98(12):2554-9. PMID: 14669273.
      View in: PubMed
    161. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 15; 21(18):3454-61. PMID: 12972520.
      View in: PubMed
    162. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 1; 21(17):3249-54. PMID: 12947059.
      View in: PubMed
    163. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15. PMID: 12855612.
      View in: PubMed
    164. Arun B. Management of women at high risk for breast cancer. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S71-7. PMID: 19795579.
      View in: PubMed
    165. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002 Oct; 12(4):319-28. PMID: 12382190.
      View in: PubMed
    166. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother. 2002 Jun; 3(6):681-91. PMID: 12036407.
      View in: PubMed
    167. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 1; 20(7):1800-8. PMID: 11919237.
      View in: PubMed
    168. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer. 2002 Mar; 9(1):15-32. PMID: 11914180.
      View in: PubMed
    169. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opin Pharmacother. 2001 Mar; 2(3):491-505. PMID: 11336601.
      View in: PubMed
    170. Arun B, Kilic G, Ashfaq R, Saboorian HM, Gokaslan T. Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest. 2001; 19(8):779-82. PMID: 11768030.
      View in: PubMed
    171. Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S, Berkarda B. Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000 Feb; 17(1):29-34. PMID: 10713657.
      View in: PubMed
    172. Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am. 2000 Jan-Feb; 6(1):21-4. PMID: 10696734.
      View in: PubMed
    173. Ozgüro?lu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, Büyükünal E, Serdengeçti S, Berkarda B. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost. 1999 Jul; 5(3):181-4. PMID: 10726005.
      View in: PubMed
    174. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A, Lippman ME. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant. 1999 Apr; 23(7):667-73. PMID: 10218842.
      View in: PubMed
    175. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. clinical and pathophysiological mechanisms and manifestations. Haemostasis. 1999; 29(2-3):111-34. PMID: 10629392.
      View in: PubMed
    176. Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines. Eur J Gynaecol Oncol. 1999; 20(3):167-71. PMID: 10410876.
      View in: PubMed
    177. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis. 1999; 29(2-3):100-10. PMID: 10629391.
      View in: PubMed
    178. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999 Jan 1; 85(1):93-9. PMID: 9921979.
      View in: PubMed
    179. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma. 1998 Nov; 31(5-6):613-5. PMID: 9922053.
      View in: PubMed
    180. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat. 1998 Feb; 47(3):269-81. PMID: 9516081.
      View in: PubMed
    181. Arun B, Udayachander M, Meenakshi A. 7,12-Dimethylbenzanthracene induced mammary tumours in Wistar rats by 'air pouch' technique--a new approach. Cancer Lett. 1984 Dec; 25(2):187-94. PMID: 6439407.
      View in: PubMed
    182. Erratum. Cancer. 120:927.
    183. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. American Journal of Cancer Research. 6:981-995.
    184. Epidemiology, Risk Factors, and Prevention. 57-87.
    185. The future is 'PARP' - Phase-II-activity of PARP inhibitor among patients with BRCA-deficient breast cancer. Breast Care. 5:364-365.
    186. Erratum. Breast Cancer Research and Treatment. 152:417.
    187. Erratum. Breast Journal. 19:460.
    188. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research. 18.
    189. Differences in quality of life between American and Chinese breast cancer survivors. Supportive Care in Cancer. 1-8.
    190. Erratum. Cancer. 121:2474-2475.
    191. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology. 27:795-800.
    192. Genotype-phenotype correlations by ethnicity and mutation location in brca mutation carriers. Breast Journal. 21:260-267.
    193. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 7:80465-80481.
    194. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Women's Oncology Review. 4:211-212.
    195. Assessing associations between the AURKAHMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One. 10.
    196. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.
    197. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications. 7.
    198. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. 16.
    199. Reply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer.
    200. Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist. 21:869-874.
    201. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. 157:319-327.
    202. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment.
    203. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 141:386-401.
    204. Herceptin plus chemotherapy combination in preoperative regimen may offer clinical benefit in early stage breast cancer. Cancer Biology and Therapy. 4.
    205. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research. 18.
    206. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics. 48:374-386.
    207. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression. Breast Cancer Research and Treatment. 161:117-134.
    208. Growth inhibition of breast cancer cells by celecoxib. Breast Cancer Research and Treatment. 69:234.
    209. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. Journal of Cancer. 6:610-615.
    210. Service delivery model and experiences in a cancer genetics clinic for an underserved population. Journal of Health Care for the Poor and Underserved. 26:784-791.
    211. 41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler. THOD - Turk Hematoloji-Onkoloji Dergisi. 15:104-109.
    212. BRCAPRO 6.0 model validation in male patients presenting for BRCA testing. Oncologist. 20:593-597.
    213. Erratum to. Breast Cancer Research and Treatment. 1.
    214. Cervical adenopathy. Consultant. 36:2345-2352.
    215. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics.
    216. THOD - Turk Hematoloji-Onkoloji Dergisi. 14:179-181.
    217. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Research and Treatment. 155:165-173.
    218. Erratum. Cancer. 118:2561.
    219. Erratum. Cancer. 118:2997.
    220. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research. 17.
    221. Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer. Cancer Research. 75:4863-4875.
    222. Examining Mediators and Moderators of Yoga for Women with Breast Cancer Undergoing Radiotherapy. Integrative Cancer Therapies. 15:250-262.
    223. American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice. 5:196-199.
    224. Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing. Frontiers in Genetics. 7.
    225. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications. 7.
    226. BRCA mutation genetic testing implications in the United States. Breast. 31:224-232.
    227. A two-stage approach to genetic risk assessment in primary care. Breast Cancer Research and Treatment. 155:375-383.
    ARUN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description